VanderLaan Paul A
Department of Pathology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts.
Cancer Cytopathol. 2015 Aug;123(8):454-60. doi: 10.1002/cncy.21560. Epub 2015 May 11.
Cytologic specimens obtained through minimally invasive biopsy techniques are increasingly being used as principle diagnostic specimens for tumors arising in multiple sites. The number and scope of ancillary tests performed on these specimens have grown substantially over the past decade, including many molecular markers that not only can aid in formulating accurate and specific diagnoses but also can provide prognostic or therapeutic information to help direct clinical decisions. Thus, the cytopathologist needs to ensure that adequate material is collected and appropriately processed for the study of relevant molecular markers, many of which are specific to tumor site. This brief review covers considerations for effective cytologic specimen collection and processing to ensure diagnostic and testing success. In addition, a general overview is provided of molecular markers pertinent to tumors from a variety of sites. The recognition of these established and emerging molecular markers by cytopathologists is an important step toward realizing the promise of personalized medicine.
通过微创活检技术获取的细胞学标本越来越多地被用作多个部位肿瘤的主要诊断标本。在过去十年中,对这些标本进行的辅助检测的数量和范围大幅增加,包括许多分子标志物,这些标志物不仅有助于做出准确和特异性的诊断,还能提供预后或治疗信息以指导临床决策。因此,细胞病理学家需要确保收集到足够的材料并进行适当处理,以研究相关分子标志物,其中许多标志物是特定于肿瘤部位的。本简要综述涵盖了有效收集和处理细胞学标本以确保诊断和检测成功的注意事项。此外,还对来自各种部位肿瘤相关的分子标志物进行了概述。细胞病理学家对这些已确立和新出现的分子标志物的认识是迈向实现个性化医疗前景的重要一步。